Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01933048 · ClinicalTrials.gov registry record · Phase 4
Self-Administered Nasal Influenza Feasibility Study
A Phase 4 study, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,077
- Enrollment target
NCT01933048 is a Phase 4 study that has completed, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 1,077 participants.
The verdict
NCT01933048, a Phase 4 study, has completed, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,077 participants
- Enrollment target
Study Summary
The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group self-administration of LAIV.
Interventions
- DRUG FluMist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,077 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01933048
The ClinicalTrials.gov registry entry for NCT01933048 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,077 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FluMist is the first listed.
NCT01933048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01933048 about?
NCT01933048 is a clinical study titled "Self-Administered Nasal Influenza Feasibility Study". The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group self-administration of LAIV.
What is the current status of trial NCT01933048?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,077 participants. The study started on 2012-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01933048?
The interventions under investigation include: FluMist (DRUG).
Who is sponsoring clinical trial NCT01933048?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.